WO2005032531A1 - Composition antimycotique - Google Patents

Composition antimycotique Download PDF

Info

Publication number
WO2005032531A1
WO2005032531A1 PCT/JP2004/011996 JP2004011996W WO2005032531A1 WO 2005032531 A1 WO2005032531 A1 WO 2005032531A1 JP 2004011996 W JP2004011996 W JP 2004011996W WO 2005032531 A1 WO2005032531 A1 WO 2005032531A1
Authority
WO
WIPO (PCT)
Prior art keywords
antifungal
weight
hydrochloride
antifungal composition
fatty acid
Prior art date
Application number
PCT/JP2004/011996
Other languages
English (en)
Japanese (ja)
Inventor
Shigeki Sawamura
Original Assignee
Kobayashi Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kobayashi Pharmaceutical Co., Ltd. filed Critical Kobayashi Pharmaceutical Co., Ltd.
Publication of WO2005032531A1 publication Critical patent/WO2005032531A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to an antifungal composition
  • an antifungal composition comprising a benzylamine antifungal agent, a fatty acid ester, a powder component, an alcoholic solvent, and an antipruritic component.
  • the present invention relates to a composition having an excellent therapeutic effect on sexual mycosis (eg, tinea pedis, tinea corporis, tinea cruris, etc.).
  • fungi In superficial mycosis, fungi mainly penetrate into the stratum corneum of the skin and proliferate. Therefore, a condition for an antifungal agent to exhibit excellent medicinal effects against superficial mycosis is that the drug itself must be used. It is necessary that the body has strong antifungal activity and high affinity for the site of infection.
  • superficial mycosis can be broadly divided into symptoms in which the affected area is relatively dry and symptoms in which the affected area is wet, and a formulation suitable for the condition of the affected area is needed.
  • benzylamine-based antifungal agents having excellent antifungal activity and keratophilicity satisfying such conditions have been put to practical use.
  • butenafine and its salt, butenafine hydrochloride are known and exhibit excellent effects when used alone.However, a formulation suitable for the condition of the affected area has not been developed. There is a demand for the development of antifungal agents that can achieve a high therapeutic effect that is more tailored to the symptoms and that can improve the patient's QOL (life comfort).
  • compositions are intended to enhance the keratin permeability of the antifungal agent, and to obtain a high therapeutic effect and a good feeling of use for wet superficial mycosis. It is not intended.
  • an antifungal composition comprising pyrrole ditrin and at least one selected from lanconazole, butenafine or a salt thereof, and an arylamine antifungal agent has been proposed.
  • composition is said to have a stronger antifungal effect than each single product, but also intended to obtain a high therapeutic effect on superficial wet mycosis and a good feeling of use. It's not something.
  • Patent Document 1 Japanese Patent No. 3081766
  • Patent Document 2 JP 2001-181182 A
  • Patent Document 3 Japanese Patent Publication No. 2000-862776
  • the present invention provides an antifungal composition capable of obtaining a high therapeutic effect tailored to the symptoms of wet superficial mycosis and achieving an improvement in Q ⁇ L of a patient.
  • the task is to do so.
  • the present inventor has found that when a specific component is added to a benzylamine antifungal agent having excellent keratin storage properties, keratin affinity, and bactericidal activity, a high therapeutic effect on a diseased part moistened by an exudate or moisture can be obtained.
  • the present inventors have found that they give a feeling of use, and have completed the present invention based on the findings.
  • the present invention provides a benzylamine antifungal agent containing a fatty acid ester, a powder component, an alcoholic solvent and an antipruritic component (the fatty acid ester, the powder component, the alcoholic solvent and the antipruritic component are referred to as compounding components).
  • An antifungal composition comprising:
  • a preferable benzylamine antifungal agent is at least one selected from the group consisting of butenafine and salts thereof.
  • the amount of the benzylamine antifungal agent is 0.01% by weight, preferably 0.05% to 5% by weight in the composition. If the amount is too small, sufficient antifungal effect will not be exhibited, and if it is too large, the safety of the composition is concerned.
  • fatty acid esters are blended for the purpose of improving the adhesiveness of the powder component at the time of drug application and the penetration of the active ingredient into the stratum corneum.
  • a high quality drug surface is formed on the affected area to achieve the above object, and further has a drug sustained release action.
  • Good Preferred fatty acid esters are isopropyl myristate, octyl myristate, butyl stearate, ethyl oleate, oleyl oleate, diisopropyl adipate, glycerin fatty acid ester, polyoxyl stearate 40, 45 and 55, and jetino sebacate.
  • sorbitan fatty acid ester isopropyl palmitate, glyceryl monooleate and sorbitan monooleate.
  • the amount of the fatty acid ester is 2 to 40% by weight, preferably 5 to 31.96% by weight in the composition. If the amount is too small, the powder component adheres poorly to the affected area, and sufficient drug permeability and sustained release cannot be obtained. If the amount is too large, a sticky feeling is given to the affected part, and a good feeling of use cannot be obtained.
  • the powder component may be organic or inorganic, and is preferably talc, zinc oxide, titanium oxide, magnesium stearate, zinc stearate, magnesium oxide, magnesium carbonate, chloramine, magnesium aluminate metasilicate, and silicate anhydride. And at least one selected from the group consisting of magnesium silicate, kaolin, aerosil, myritsu, and corn starch.
  • the mixing ratio of the powder component is 15 to 70% by weight, preferably 20 to 50% by weight. If the amount is too small, the feeling of use is poor. If the amount is too large, the excessive amount of powder prevents the drug from adhering to and penetrating the affected area.
  • the antipruritic component is compounded for the purpose of suppressing the pruritus of Megumi, preventing the affected area from being exacerbated by pimples, and preventing drug dropout.
  • the amount of the antipruritic component is 0.01 to 20% by weight, preferably 0.05 to 10% by weight in the composition. If the amount is too small, a sufficient antifungal effect will not be exhibited, and if it is too large, the safety of the composition is concerned.
  • Preferred antipruritic components include lidocaine, dibu-force, pro-force, dibu-force, hydrochloride, lidocaine-hydrochloride, pro-force, hydrochloride, aminoethyl benzoate, oxypolyentoxide dodecane, diphenylpyralin hydrochloride, diphenhydramine hydrochloride, chlorphen. At least one selected from the group consisting of biramine, diphenhydramine salicylate, and crotamiton.
  • the alcohol-based solvent dissolves the antifungal agent, and is blended for the purpose of enhancing the permeability to the keratin and the therapeutic effect.
  • the amount of the alcohol solvent is 1580% by weight, preferably 29.94 74.9% by weight in the composition. If the amount is too small, the antifungal agent will not dissolve in the solvent, and sufficient drug effect will not be obtained. If the amount is too large, the solvent may be And prevents the formation of a homogeneous drug surface.
  • Preferred alcohol solvents are at least one selected from the group consisting of methanol, ethanol, propanol, butanol, benzyl alcohol, glycerin, ethylene glycol and their structural isomers (eg, isopropanol, t-butanol, etc.).
  • antifungal agents 0. 01- 10 wt%, more preferably rather is 0.5 05 5 wt 0/0, 2 40 wt month effect fatty acid Esutenore 0/0, more preferably 5 31.96 by weight%, the powder component 15 70 wt%, more preferably 20- 50 wt%, the alcohol solvent 15 80 wt%, more preferably 29.94 74.9 wt%, and the antipruritic ingredient 0.0 1 one 20 weight 0/0, but more preferably including 0.05 to 10 wt 0/0.
  • an aerosol comprising the antifungal composition 5 having the above constitution in an amount of 5 to 30% by weight and a propellant in an amount of from 95 to 70% by weight.
  • propellants comprise at least one liquefiable aliphatic hydrocarbon such as propane, butanes, pentane, isopentane, neopentane, and the like.
  • the antifungal composition according to the present invention includes, in addition to the benzylamine antifungal agent and the above-mentioned components, a preservative, a preservative, a lubricant, a chelating agent, a fragrance, a solvent, a solubilizing agent, a pH adjusting agent. , Antioxidants, moisturizers, shape-retaining agents (hereinafter referred to as “additives”), anti-inflammatory agents, cooling agents, bactericides, astringents, blood circulation promoters, skin protectants, tissue repair agents, etc. (Hereinafter, referred to as “other active ingredients”) as necessary.
  • anti-inflammatory agent examples include glycyrrhetinic acid, dipotassium glycyrrhizinate, allantoin, 1 menthol, dl menthol, and dl camphor.
  • the antifungal composition according to the present invention is used in a usual dosage form used for treating a skin disease.
  • dosage forms include solutions, ointments (oil-based ointments, emulsion ointments, water-soluble ointments), rementions, lotions, powders, emulsified suspensions, tinctures, vaginal suppositories, aerosols And the like, and an aerosol is preferable.
  • the antifungal composition according to the present invention can be formulated into the above-mentioned dosage form by a conventional method using an appropriate base.
  • a base to which polymers such as cibininole polymer, ethi / resenorelose, methinores / rerose, hydroxypropyl / resenorelose, carboxymethylcellulose, purified water, propellant, and phenols are added.
  • a typical formulation is prepared as follows.
  • the solution is prepared by adding a benzylamine-based antifungal agent, a compounding component, an additive component added as necessary, and other active components to an alcohol-based solvent or a base obtained by adding purified water or the like to the solution. Mix evenly.
  • the ointment is prepared by adding an alcoholic solvent to a base obtained by adding petrolatum, white wax, paraffin, vegetable oil, plastic base, polyethylene glycol, macrogol, etc. to a benzylamine antifungal agent, compounding ingredients, It is made by uniformly mixing the added ingredients and other active ingredients accordingly.
  • the gel is prepared by mixing a carboxyvinyl polymer, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polybutyl alcohol, polybutylpyridone, purified water and the like in an alcohol solvent, and a benzylamine antifungal agent. It is a gel obtained by uniformly mixing the ingredients, the ingredients added as needed, and other active ingredients.
  • the aerosol is prepared by adding a benzylamine-type antifungal agent, a compounding component, an additive component added as needed, and other active components to an alcohol-based solvent or a base obtained by adding purified water or the like to the solvent.
  • the mixture is mixed homogeneously, and the resulting mixture is filled in a container equipped with a valve, an actuator and the like, together with a propellant such as a liquefiable hydrocarbon, for example, propane, butane granule, pentane, isopentane, neopentane, or a mixture thereof. It becomes.
  • the dosage of the pendinoleamine-based antifungal agent in the antifungal composition according to the present invention is selected according to the dosage form, the content ratio of the active ingredient to the compounding ingredient, the type of fungus, the degree of symptoms, and the like.
  • the force is in the range of 0.01 mg / day, preferably 0.05 mg / day.
  • the frequency of administration is once a day.
  • a specific component is blended with a pendinoleamine-based antifungal agent having excellent keratin storage properties, keratin affinity and bactericidal activity, thereby adjusting to the symptoms of wet superficial mycosis.
  • a pendinoleamine-based antifungal agent having excellent keratin storage properties, keratin affinity and bactericidal activity, thereby adjusting to the symptoms of wet superficial mycosis.
  • Butenafine hydrochloride g Diphenhydramine hydrochloride 2 g Daritinoleretinic acid lg Chlorhexidine hydrochloride lg Zinc oxide 10 g Tanolek 10 g Isopropyl myristate 30 g Ethanore 45 g Total amount 100 g
  • Butenafine hydrochloride lg Lidocaine 2.5 g Daritinoleretic acid lg Zinc oxide 10 g Tanolek 20 g Isopropyl myristate 20 g lOOg
  • the antifungal composition Sampnore of Example 1 and Comparative Examples 14 to 14 having the compounding ratios shown in Table 1 was evaluated for feeling of use by the following method. In other words, apply the test sample to the same place between the toes of the 7 panelists, apply easily at the time of application, easy to dry, 8 hours after application, the smoothness of the applied area (between the toes), and A score was given for the overall feeling of use based on the overall evaluation based on the following evaluation criteria.
  • a 6-week-old ddY-type clean mouse male was kept for 1 week, acclimated, and used for the test.
  • the weight of the mouse was measured, and the back was shaved with a clipper.
  • 200 mg of the test sample was applied to the shaved portion, and the finger was printed 20 times with a finger.
  • 30 minutes after application of the test sample ether anesthesia was performed, and the itch-inducing substance was intradermally administered at a rate of 20 per mouse weighing 40 g (lml micro syringe, 26G x 1 / 2.45 x 13m m injection needle).
  • Table 7 shows the obtained results. Table 7 shows that the composition of Example 1 exerts a good antipruritic effect.
  • the bacteria were cultured on Sabouraud agar slant medium (manufactured by Eiken Chemical Co., Ltd.) for 14 days at 27 ° C. Then, sterile saline was added to release the bacteria, and a sterilized filter (100 ⁇ , cell (Strainer: manufactured by FALCON) to prepare a bacterial solution of 2 ⁇ 10 7 / ml.
  • Guinea pigs were bred for 1 week, acclimated, and then tested.
  • the back of the guinea pig was depilated under anesthesia with bentovalpital sodium (50 mg / ml / kg; Nembutal injection (manufactured by Dainippon Pharmaceutical Co., Ltd.) in the abdomen).
  • bentovalpital sodium 50 mg / ml / kg; Nembutal injection (manufactured by Dainippon Pharmaceutical Co., Ltd.) in the abdomen).
  • 6 test sites of 2 cm ⁇ 2 cm were provided at 2 cm intervals so that the test substance did not cross.
  • the hair removal site was stripped three times with a 2 cm square cloth adhesive tape to remove the upper part of the stratum corneum of the skin. After disinfecting the skin surface with alcohol wool, 0.1 ml of bacterial solution was inoculated per site.
  • test animals After inoculation, the test animals are kept at a humidity of 60-68% and a temperature of 27 ° C. From the 5th day after inoculation, 0.3 g of the test sample is applied once a day continuously for 8 days. Imprinted with fingers 20 times. The degree of lesion at the infected site was observed once a day and scored according to the following criteria. [0045] Evaluation criteria for lesion degree
  • Test starting power is also on day 13 (drug The efficacy of the antifungal activity of the test sample was evaluated based on the average value of the scores at the six test sites (day 8 from the start of application).
  • Table 8 shows the obtained results. Table 8 shows that the composition of Example 1 exhibits effective antifungal activity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention vise à obtenir un produit ayant un effet thérapeutique élevé contre les symptômes de la mycose superficielle suintante. On prépare une telle composition antimycotique en mélangeant un agent antimycotique du type benzylamine avec un ester d'acides gras, un composant pulvérulent, un solvant à base d'alcool et un composant contre les démangeaisons. Comme agent antimycotique du type benzylamine, il est préférable d'utiliser au moins un élément choisi dans le groupe constitué par la buténafine et ses sels. L'agent antimycotique du type benzylamine est contenu dans la composition en quantité comprise entre 0,05 et 5 % en poids.
PCT/JP2004/011996 2003-09-30 2004-08-20 Composition antimycotique WO2005032531A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003341723A JP2005104917A (ja) 2003-09-30 2003-09-30 抗真菌組成物
JP2003-341723 2003-09-30

Publications (1)

Publication Number Publication Date
WO2005032531A1 true WO2005032531A1 (fr) 2005-04-14

Family

ID=34419218

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/011996 WO2005032531A1 (fr) 2003-09-30 2004-08-20 Composition antimycotique

Country Status (3)

Country Link
JP (1) JP2005104917A (fr)
TW (1) TW200511986A (fr)
WO (1) WO2005032531A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3800232B2 (ja) * 2004-09-30 2006-07-26 小林製薬株式会社 抗真菌性外用組成物
JP5872131B2 (ja) * 2006-11-29 2016-03-01 ロート製薬株式会社 抗真菌医薬組成物
JP6930343B2 (ja) * 2017-09-29 2021-09-01 信越化学工業株式会社 消臭・抗菌・抗カビ剤含有分散液、その製造方法、及び消臭・抗菌・抗カビ剤を表面に有する部材

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11106332A (ja) * 1997-08-07 1999-04-20 Taisho Pharmaceut Co Ltd 粉末エアゾール製剤
JP2001181182A (ja) * 1999-12-22 2001-07-03 Takeda Chem Ind Ltd 抗真菌性液体外用組成物
JP2001233764A (ja) * 2000-02-22 2001-08-28 Hisamitsu Pharmaceut Co Inc Ｎ−置換−ｏ−トルイジン誘導体からなる鎮痒剤
JP2002284702A (ja) * 2001-01-19 2002-10-03 Teika Seiyaku Kk 外用抗真菌製剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11106332A (ja) * 1997-08-07 1999-04-20 Taisho Pharmaceut Co Ltd 粉末エアゾール製剤
JP2001181182A (ja) * 1999-12-22 2001-07-03 Takeda Chem Ind Ltd 抗真菌性液体外用組成物
JP2001233764A (ja) * 2000-02-22 2001-08-28 Hisamitsu Pharmaceut Co Inc Ｎ−置換−ｏ−トルイジン誘導体からなる鎮痒剤
JP2002284702A (ja) * 2001-01-19 2002-10-03 Teika Seiyaku Kk 外用抗真菌製剤

Also Published As

Publication number Publication date
TW200511986A (en) 2005-04-01
JP2005104917A (ja) 2005-04-21

Similar Documents

Publication Publication Date Title
AU2016277570B2 (en) Compositions and methods for treating diseases of the nail
JP4828563B2 (ja) 水虫治療用外用剤
US20060078580A1 (en) Organo-gel formulations for therapeutic applications
US20060078579A1 (en) Organo-gel formulations for therapeutic applications
US8889155B2 (en) Gel composition for treating mycosis
KR20110125660A (ko) 가온성 및 무자극성 윤활제 항진균성 겔 조성물
JP2011500779A (ja) 新規製剤
NZ251783A (en) Antimicrobial compositions comprising monoglyceride of lauric or monomyriotic acid with urea, fusidic acid, econazole nitrate, mikonazole nitrate, tinidazole, metronidazole or petanediol
MXPA06012426A (es) Suministro de farmaco antifungico.
CA2484318C (fr) Compositions de gel antifongiques lubrifiantes, non irritantes et chauffantes
JP5033381B2 (ja) 外用医薬組成物
JP2006232856A (ja) 抗真菌組成物
WO2005099764A1 (fr) Composition antifongique pour usage externe
US20040185065A1 (en) Warming and nonirritating lubricant compositions and method of comparing irritation
WO2011061155A1 (fr) Formulations antifongiques et leur utilisation
WO2005032531A1 (fr) Composition antimycotique
WO2005032532A1 (fr) Composition fongicide
WO2005032557A1 (fr) Composition fongicide
EP1656125A2 (fr) Composition topique comprenant de la terbinafine et de l'hydrocortisone
JP5097363B2 (ja) 抗真菌組成物
JP2006232854A (ja) 抗真菌組成物
JP2004203895A (ja) 外用抗真菌剤
JP2012126733A (ja) 外用医薬組成物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase